Chimeric antigen receptor T-cell therapy for marrow and extramedullary relapse of infant acute lymphoblastic leukemia. Pediatr Blood Cancer 2021 Jan;68(1):e28739
Date
10/04/2020Pubmed ID
33009894DOI
10.1002/pbc.28739Scopus ID
2-s2.0-85091860342 (requires institutional sign-in at Scopus site) 10 CitationsAbstract
Chimeric antigen receptor (CAR) T-cells, engineered autologous T-cells that target antigens found in leukemia, have shown durable remissions in relapsed acute lymphoblastic leukemia (ALL). Infant ALL with KMT2A rearrangements (KMT2Ar) is a rare, aggressive form of leukemia associated with extramedullary disease both at diagnosis and at relapse, and overall outcomes for these patients are dismal. Here we report the successful use of tisagenlecleucel, a CAR T-cell product approved for relapsed/refractory ALL, in a patient with KMT2Ar infant ALL who was treated for combined marrow and extramedullary (renal) relapse.
Author List
Moskop A, Pommert L, Thakrar P, Talano J, Phelan RAuthors
Amy Moskop MD Assistant Professor in the Pediatrics department at Medical College of WisconsinRachel A. Phelan MD, MPH Associate Professor in the Pediatrics department at Medical College of Wisconsin
Julie-An M. Talano MD Professor in the Pediatrics department at Medical College of Wisconsin
Pooja Thakrar MD Associate Professor in the Radiology department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
Antineoplastic Combined Chemotherapy ProtocolsBone Marrow Neoplasms
Combined Modality Therapy
Female
Hematopoietic Stem Cell Transplantation
Histone-Lysine N-Methyltransferase
Humans
Immunotherapy, Adoptive
Infant
Kidney Neoplasms
Mutation
Myeloid-Lymphoid Leukemia Protein
Neoplasm Recurrence, Local
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Prognosis
